Variables | Stage III | Stage IV | ||||||
---|---|---|---|---|---|---|---|---|
Groups | 3 ≤ OS < 5 | 5 ≤ OS (tumor +) | 5 ≤ OS (tumor -): CR | P value | 3 ≤ OS < 5 | 5 ≤ OS (tumor +) | 5 ≤ OS (tumor -): CR | P value |
Chemotherapy | ||||||||
 Treatment line No. (mean ± SD) | 3.7 ± 2.0 | 3.7 ± 2.8 | 1.7 ± 1.0* | < 0.05 | 5.9 ± 2.5 | 5.5 ± 3.4 | 2.0 ± 1.4* | < 0.05 |
 Total cycle No. (include EGFR-TKI#) (mean ± SD) | 16.3 ± 10.2 | 20.3 ± 19.6 | 10.2 ± 11.7 | 0.20 | 23.8 ± 13.6 | 25.1 ± 18.4 | 5.4 ± 3.5*# | < 0.05 |
EGFR-TKI usage | ||||||||
 +; no. (%) | 4 (31%) | 3 (25%) | 0 (0%) | 0.12 | 20 (69%) | 11 (65%) | 1 (20%) | 0.11 |
 -; no. (%) | 9 (69%) | 9 (75%) | 12 (100%) |  | 9 (31%) | 6 (35%) | 4 (80%) |  |
 EGFR-TKI line No. | 0.5 ± 0.8min: 1, max: 2 | 0.5 ± 1.0 min: 1, max: 3 | 0 | 0.13 | 1.5 ± 1.3 min: 1, max: 4 | 1.1 ± 1.1 min: 1, max: 3 | 0.4 ± 0.9 min: 2, max: 2 | 0.15 |
Radiation | ||||||||
 Primary | ||||||||
  +; no. (%) | 11 (85%) | 8 (67%) | 12 (100%) | 0.09 | 5 (17%) | 4 (24%) | 2 (40%) | 0.51 |
  -; no. (%) | 2 (15%) | 4 (33%) | 0 (0%) |  | 24 (83%) | 13 (76%) | 3 (60%) |  |
Metastatic lesions other than brain | ||||||||
 +; no. (%) | 1 (8%) | 3 (25%) | 3 (25%) | 0.43 | 11 (38%) | 5 (29%) | 2 (40%) | 0.82 |
 -; no. (%) | 12 (92%) | 9 (75%) | 9 (75%) |  | 18 (62%) | 12 (71%) | 3 (60%) |  |
Both primary and metastatic lesions other than brain | ||||||||
 +; no. (%) | 1 (8%) | 3 (25%) | 3 (25%) | 0.43 | 2 (7%) | 1 (6%) | 0 (0%) | 0.83 |
 -; no. (%) | 12 (92%) | 9 (75%) | 9 (75%) |  | 27 (93%) | 16 (94%) | 5 (100%) |  |
Surgery | ||||||||
 Primary | ||||||||
  +; no. (%) | 1 (8%) | 3 (25%) | 0 (0%) | 0.13 | 2 (7%) | 1 (6%) | 2 (40%) | 0.06 |
  -; no. (%) | 12 (92%) | 9 (75%) | 12 (100%) |  | 27 (93%) | 16 (94%) | 3 (60%) |  |
Metastatic lesions other than brain | ||||||||
 +; no. (%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.00 | 0 (0%) | 0 (0%) | 2 (40%) | < 0.05 |
 -; no. (%) | 13 (100%) | 12 (100%) | 12 (100%) |  | 29 (100%) | 17 (100%) | 3 (60%) |  |
Both primary and metastatic lesions other than brain | ||||||||
 +; no. (%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.00 | 0 (0%) | 0 (0%) | 1 (20%) | < 0.05 |
 -; no. (%) | 13 (100%) | 12 (100%) | 12 (100%) |  | 29 (100%) | 17 (100%) | 4 (80%) |  |
Treatment of brain metastases | ||||||||
 SRT |  |  |  |  |  |  |  |  |
 +; no. (%) | 1 (8%) | 3 (25%) | 0 (0%) | 0.13 | 8 (28%) | 5 (29%) | 1 (20%) | 0.92 |
 -; no. (%) | 12 (92%) | 9 (75%) | 12 (100%) |  | 21 (72%) | 12 (71%) | 4 (80%) |  |
Surgery | ||||||||
 +; no. (%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.00 | 1 (3%) | 1 (6%) | 1 (20%) | 0.35 |
 -; no. (%) | 13 (100%) | 12 (100%) | 12 (100%) |  | 28 (97%) | 16 (94%) | 4 (80%) |  |
WBI | ||||||||
 +; no. (%) | 1 (8%) | 1 (8%) | 0 (0%) | 0.60 | 7 (24%) | 3 (18%) | 0 (0%) | 0.44 |
 -; no. (%) | 12 (92%) | 11 (92%) | 12 (100%) |  | 22 (76%) | 14 (82%) | 5 (100%) |  |